PURPOSE: To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT). METHODS AND MATERIALS: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. RESULTS: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. CONCLUSIONS: There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.
RCT Entities:
PURPOSE: To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT). METHODS AND MATERIALS: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. RESULTS: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. CONCLUSIONS: There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Meetha Medhora; Feng Gao; Qingping Wu; Robert C Molthen; Elizabeth R Jacobs; John E Moulder; Brian L Fish Journal: Radiat Res Date: 2014-10-31 Impact factor: 2.841
Authors: Marek Lenarczyk; Eric P Cohen; Brian L Fish; Amy A Irving; Mukut Sharma; Collin D Driscoll; John E Moulder Journal: Radiat Res Date: 2009-02 Impact factor: 2.841
Authors: Laura E Villasana; Rosalind A Rosenthal; Susan R Doctrow; Timothy Pfankuch; Damian G Zuloaga; Alexandra Maccoll Garfinkel; Jacob Raber Journal: Pharmacol Biochem Behav Date: 2012-10-07 Impact factor: 3.533
Authors: Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker Journal: Biol Blood Marrow Transplant Date: 2012-01-14 Impact factor: 5.742
Authors: Eric P Cohen; Manpreet Bedi; Amy A Irving; Elizabeth Jacobs; Rade Tomic; John Klein; Colleen A Lawton; John E Moulder Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038